US Bancorp
SYRE icon

US Bancorp’s Spyre Therapeutics SYRE Stock Holding History

US Bancorp’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$134K Buy
1,507
+1,410
+1,454% +$103K ﹤0.01% 2306
2026
Q1 		$4.89K Buy
97
+87
+870% +$3.28K ﹤0.01% 3580
2025
Q4 		$328 Hold
10
– – ﹤0.01% 3952
2025
Q3 		$168 Hold
10
– – ﹤0.01% 3953
2025
Q2 		$150 Buy
10
+1
+11% +$15 ﹤0.01% 4094
2025
Q1 		$145 Buy
+9
New +$187 ﹤0.01% 4118
2024
Q4 		– Sell
-9
Closed -$265 – 4264
2024
Q3 		$265 Buy
+9
New +$251 ﹤0.01% 3991

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

US Bancorp's SYRE Position: Q2 2026 in Review

US Bancorp increased its Spyre Therapeutics (SYRE) stake by 1,454% in Q2 2026, buying an estimated $103K and bringing the position to 1,507 shares worth $134K. The position accounts for ﹤0.01% of the portfolio, ranked #2306.

US Bancorp first reported a position in SYRE in Q3 2024 and has held it in 7 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • US Bancorp held 1,507 shares of Spyre Therapeutics worth $134K as of Q2 2026.
  • US Bancorp bought 1,410 Spyre Therapeutics shares in Q2 2026, an estimated $103K.
  • Spyre Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2306 holding.
  • US Bancorp first reported a position in Spyre Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.